25 July, 2025Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
22 July, 2025Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
22 July, 2025Introducing Latent-X, a frontier generative AI model for protein binder design accessible via no-code platform for push-button protein design
17 July, 2025One Biosciences announces €15 Million Series A financing to advance clinical single cell profiling